logo
Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Ohtuvayre TM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024
More prescriptions filled through February 2025 than in Q4 2024
Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025
Phase 2 programs in bronchiectasis and fixed-dose combination in COPD advance
Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT
LONDON and RALEIGH, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ('Verona Pharma' or the 'Company'), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2024, and provides a corporate update.
'2024 was another transformational year for Verona Pharma with the US approval and launch of Ohtuvayre (ensifentrine), the first novel inhaled therapy available for the maintenance treatment of Chronic Obstructive Pulmonary Disease ('COPD') in over 20 years,' said David Zaccardelli, Pharm. D., President and Chief Executive Officer. 'We are very pleased to report the extremely strong start to the launch continues to build momentum with more prescriptions dispensed through February 2025 than in the entire fourth quarter of 2024.
'More than 4,600 unique healthcare professionals ('HCPs') including approximately 55% of our Tier 1 HCPs have prescribed Ohtuvayre. Additionally, to date, more than 275 HCPs have prescribed Ohtuvayre to over 20 patients in their practice. Ohtuvayre is being prescribed for maintenance therapy across a broad COPD population including those receiving background single, dual and approximately 50% on triple therapy. These data strengthen our belief that ensifentrine's novel bronchodilator and non-steroidal anti-inflammatory activity will redefine the treatment paradigm for COPD.
'Alongside our commercialization efforts, in the third quarter we initiated two Phase 2 clinical trials: a dose-ranging trial with glycopyrrolate, a long-acting muscarinic antagonist ('LAMA'), to support a nebulized fixed-dose combination of ensifentrine and glycopyrrolate for the maintenance treatment of COPD, and a study assessing the safety and efficacy of nebulized ensifentrine in patients with non-cystic fibrosis bronchiectasis ('bronchiectasis'). We are pleased to report the glycopyrrolate dose-ranging trial was successfully completed and we plan to initiate a dose ranging Phase 2b trial with a fixed-dose combination of ensifentrine and glycopyrrolate in the second half of 2025.
'In addition to our successful Ohtuvayre launch, our development partner in Greater China, Nuance Pharma, announced in February 2025 that Ohtuvayre was approved in Macau, the first approval outside of the US, for the maintenance treatment of COPD. In addition, Nuance Pharma has completed enrollment in its own pivotal Phase 3 trial in China to evaluate ensifentrine for the maintenance treatment of COPD and expects to report results in mid-2025.
'In 2025, we will continue to build on the successful commercialization of Ohtuvayre in the US while progressing our Phase 2 programs. We are also initiating activities with regulatory authorities in the European Union and the UK for potential marketing authorization application submissions for Ohtuvayre.'
Program Updates and Key Milestones
The Company's near-term milestones include:
In the second half of 2025, the Company plans to start a dose-ranging Phase 2b trial to assess the safety and efficacy of a fixed-dose nebulized combination of ensifentrine with glycopyrrolate. The Company has successfully completed a Phase 2 dose-ranging trial with glycopyrrolate to support this program.
The Company continues to enroll subjects in a Phase 2 trial to assess the efficacy and safety of nebulized ensifentrine in patients with bronchiectasis.
In 2025, the Company plans to progress the regulatory activities for potential marketing authorization application submissions for Ohtuvayre for the maintenance treatment of COPD in the European Union and in the UK.
In mid-2025, the Company's development partner in Greater China, Nuance Pharma, is expected to report results from its pivotal Phase 3 trial evaluating ensifentrine for the maintenance treatment of COPD in China.
Fourth Quarter and Recent Highlights
In October 2024, the Company gave four oral presentations and presented two posters on analyses from the ENHANCE studies at CHEST Annual Meeting 2024. These included subgroup data supporting improvements in lung function, symptoms and quality of life, as well as reductions in the rate of exacerbations, regardless of COPD severity (moderate or severe), smoking status (current or former) and chronic bronchitis (with or without). An analysis of Ohtuvayre's impact on reducing exacerbation rates and COPD-related healthcare resource utilization was also presented.
In November 2024, the 2025 GOLD report added Ohtuvayre to the COPD treatment algorithm.
Also in November 2024, the Company completed enrollment in a Phase 2 dose-ranging trial with glycopyrrolate, a LAMA, supporting a fixed-dose combination program for the maintenance treatment of COPD via a nebulizer.
On January 1, 2025, Ohtuvayre's product specific J-code became effective.
In February 2025, the Company's development partner in Greater China, Nuance Pharma, announced Ohtuvayre has been approved in Macau for the maintenance treatment of COPD in adult patients. This is the first regulatory approval outside of the US.
Fourth Quarter 2024 Financial Results
Cash position: Cash and cash equivalents at December 31, 2024, were $399.8 million (December 31, 2023: $271.8 million).
Product sales: Net sales of Ohtuvayre were $36.6 million for the fourth quarter ended December 31, 2024 (Q4 2023: $0 million). The Company received FDA approval on June 26, 2024 and the product was commercially available beginning in August 2024.
Cost of sales: Cost of sales was $2.0 million for the fourth quarter ended December 31, 2024 (Q4 2023: $0 million), which included Ohtuvayre manufacturing costs incurred after US approval, inventory overhead costs and sales-based royalties.
R&D Expenses: Research and development ('R&D') expenses were $7.9 million for the fourth quarter ended December 31, 2024 (Q4 2023: $4.1 million). This increase of $3.8 million was primarily due to an increase of $3.2 million in clinical trial and other development costs as we initiated two Phase 2 studies in the third quarter of 2024 related to the combination of nebulized ensifentrine and glycopyrrolate and for Ohtuvayre in patients with bronchiectasis, and an increase of $1.1 million in share-based compensation.
SG&A Expenses: Selling general and administrative expenses ('SG&A') were $45.1 million for the fourth quarter ended December 31, 2024 (Q4 2023: $15.0 million). The increase of $30.1 million was driven primarily by an increase of $9.8 million in marketing and other commercial related activities, including travel, primarily related to the launch of Ohtuvayre, and an increase of $2.6 million in professional and consulting fees, information technology costs and other support costs due to the continued buildout of our commercial organization. Additionally, we had an increase of $8.8 million in people-related costs as we built out our commercial organization including much of the field sales team as well as an increase of $7.8 million related to share-based compensation.
Net loss: Net loss was $33.8 million for the fourth quarter ended December 31, 2024 (Q4 2023: Net loss $14.1 million).
Full Year 2024 Financial Results
Product sales: Net sales were $42.3 million for the year ended December 31, 2024 (2023: $0 million) related to product sales of Ohtuvayre.
Cost of sales: Cost of sales was $2.6 million for the year ended December 31, 2024 (2023: $0 million), which included Ohtuvayre manufacturing costs incurred after US approval, inventory overhead costs and sales-based royalties.
R&D Expenses: R&D expenses were $44.6 million for the year ended December 31, 2024 (full year 2023: $17.2 million), an increase of $27.4 million. This increase was primarily due to an increase of $17.5 million in clinical trial and other development costs we incurred related to the two Phase 2 studies which were initiated in the third quarter of 2024 related to the combination of nebulized ensifentrine and glycopyrrolate and for Ohtuvayre in patients with bronchiectasis, the $6.3 million approval milestone, $3.1 million increase in share-based compensation, $2.0 million increase for people-related costs and $1.1 million related to pre-launch manufacturing costs for commercial supply. This was partially offset by a decrease of $1.3 million in consultant and professional fee costs which were higher in the prior year due to service costs associated with our New Drug Application and the related approval process.
SG&A Expenses: SG&A expenses were $149.8 million for the year ended December 31, 2024 (full year 2023: $50.4 million), an increase of $99.4 million. This increase was driven primarily by an increase of $29.7 million in marketing and other commercial related activities, including travel, primarily related to the launch of Ohtuvayre, a charge of $15.0 million for the first sale milestone and an increase of $7.3 million in professional and consulting fees, information technology costs and other support costs due to the continued buildout of our commercial organization. Additionally, we had an increase of $26.8 million in people-related costs as we built out our commercial organization including much of the field sales team as well as an increase of $18.8 million related to share-based compensation.
Net loss: Net loss was $173.4 million for the year ended December 31, 2024 (full year 2023: $54.4 million).
Conference Call and Webcast Information
Verona Pharma will host an investment community webcast and conference call at 9:00 a.m. EST / 2:00 p.m. GMT on Thursday, February 27, 2025, to discuss the fourth quarter and full year 2024 financial results and the corporate update.
To participate, please dial one of the following numbers and ask to join the Verona Pharma call:
+1-800-836-8184 for callers in the United States
+1-646-357-8785 for international callers
A live webcast will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com, and the audio replay will be available for 90 days. An electronic copy of the fourth quarter and full year 2024 results press release will also be made available today on the Company's website.
Important Safety Information
Indication
Ohtuvayre is a prescription medicine used to treat COPD in adults. COPD is a chronic (long-term) lung disease that includes chronic bronchitis, emphysema, or both.
What is the most important information I should know about Ohtuvayre?
Ohtuvayre can cause serious side effects, including:
Sudden breathing problems immediately after inhaling your medicine. If you have sudden breathing problems immediately after inhaling your medicine, stop using Ohtuvayre and call your healthcare provider right away or go to the nearest hospital emergency room right away.
Mental health problems including suicidal thoughts and behavior. You may experience mood or behavior changes when taking Ohtuvayre. Call your healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you: thoughts of suicide or dying, attempt to commit suicide, trouble sleeping (insomnia), new or worse anxiety, new or worse depression, acting on dangerous impulses, and/or other unusual changes in your behavior or mood.
Do not use Ohtuvayre to treat sudden breathing problems. Always have a rescue inhaler with you.
Who Should Not use Ohtuvayre?
Do not use Ohtuvayre if you have had an allergic reaction to ensifentrine or any of the ingredients in Ohtuvayre.
What should I tell my healthcare provider before using Ohtuvayre?
Before you use Ohtuvayre, tell your healthcare professional if you have or have had a history of mental health problems including depression and suicidal behavior; have liver problems; are pregnant or plan to become pregnant; are breastfeeding. It is not known if Ohtuvayre may harm your unborn baby. It is not known if the medicine in Ohtuvayre passes into your breast milk and if it can harm your baby.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the most common side effects of Ohtuvayre?
The most common side effects of Ohtuvayre include back pain, high blood pressure, bladder infection and diarrhea.
These are not all the possible side effects of Ohtuvayre. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
This summary does not include all the information about Ohtuvayre and is not meant to take the place of a discussion with your healthcare provider about your treatment.
For further information, please see the full Prescribing Information, including the Patient Information Leaflet.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
For further information please contact:
About Verona Pharma
Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. OhtuvayreTM (ensifentrine) is the Company's first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements. Words such as 'anticipate,' 'believe,' 'plan,' 'expect,' 'intend,' 'may,' 'potential,' 'prepare,' 'possible' and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the potential benefits and efficacy of our drug Ohtuvayre to treat adult patients in the US with COPD, statements regarding our two recently initiated Phase 2 clinical trials, the Company's plans to initiate a Phase 2b clinical trial, potential regulatory approvals in the EU and UK, and Nuance Pharma's results from its pivotal Phase 3 trial, and the timing of any of the foregoing.
These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: risks related to our limited operating history; our need for additional funding to complete development and commercialization of Ohtuvayre which may not be available and which may force us to delay, reduce or eliminate our development or commercialization efforts; our reliance on the success of Ohtuvayre, our only commercial product; our reliance on third-party manufacturers and suppliers; the efficacy of Ohtuvayre compared to competing drugs; our ability to successfully commercialize Ohtuvayre; serious adverse, undesirable or unacceptable side effects associated with Ohtuvayre which could adversely affect our ability to commercialize Ohtuvayre; failure to develop Ohtuvayre for additional indications, alternate delivery methods, or as a combination therapy; failure to obtain approval for and commercialize Ohtuvayre in multiple major pharmaceutical markets; our commercial capabilities and infrastructure, including sales, marketing, operations, distribution, and reimbursement infrastructure, may not be adequate to successfully commercialize Ohtuvayre; lawsuits related to patents covering Ohtuvayre and the potential for our patents to be found invalid or unenforceable; lawsuits related to our licensing of patents and know-how from third parties for the commercialization of Ohtuvayre; changes in our tax rates, unavailability of certain tax credits or reliefs or exposure to additional tax liabilities or assessments that could affect our profitability, and audits by tax authorities that could result in additional tax payments for prior periods; the terms of our credit agreement and the revenue interest purchase and sale agreement ('RIPSA') place restrictions on our operating and financial flexibility, and if we fail to comply with certain covenants in the RIPSA, our results of operations and financial condition may be harmed; our vulnerability to natural disasters, global economic factors, geo-political actions and unexpected events, including health epidemics or pandemics; and the other important factors discussed under the caption 'Risk Factors' in our Annual Report on Form 10-K for the period ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on February 27, 2025, as such factors may be updated from time to time in our other filings with the SEC. We disclaim any obligation to update or revise any forward-looking statement contained in this press release, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Verona Pharma plc
Consolidated Financial Summary
(unaudited)
(in thousands, except share and per share amounts)
Three months ended December 31, Years ended December 31,
2024 2023 2024 2023
Revenue
Product sales, net $ 36,637 $ — $ 42,261 $ —
Other revenue 18 — 18 —
Total Revenue, net 36,655 — 42,279 —
Operating expenses
Cost of sales 2,039 — 2,582 —
Research and development 7,870 4,122 44,574 17,216
Selling, general and administrative 45,085 14,972 149,750 50,353
Total operating expenses 54,994 19,094 196,906 67,569
Operating loss (18,339) (19,094) (154,627) (67,569)
Other income/(expense)
Research & development tax credit 556 1,034 3,600 1,104
Loss on extinguishment of debt — — (3,653) —
Interest income 3,994 3,292 15,262 12,761
Interest expense (10,317) (623) (23,542) (2,057)
Foreign exchange gain/(loss) (1,450) 1,206 (169) 1,866
Total other income/(expense), net (7,217) 4,909 (8,502) 13,674
Loss before income taxes (25,556) (14,185) (163,129) (53,895)
Income tax benefit/(expense) (8,271) 53 (10,289) (474)
Net loss $ (33,827) $ (14,132) $ (173,418) $ (54,369)
Weighted average shares outstanding – basic and diluted 663,263,855 642,139,211 652,310,582 634,142,660
Loss per ordinary share - basic and diluted $ (0.05) $ (0.02) $ (0.27) $ (0.09)
2024 2023
Cash and cash equivalents $ 399,757 $ 271,772
Total assets 474,242 308,124
Shareholders' equity $ 204,559 $ 249,283
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Jetoptera and Eanan J500 VTOL Cargo UAS Turbocompressor Map Testing Campaign
Jetoptera and Eanan J500 VTOL Cargo UAS Turbocompressor Map Testing Campaign

Hamilton Spectator

time42 minutes ago

  • Hamilton Spectator

Jetoptera and Eanan J500 VTOL Cargo UAS Turbocompressor Map Testing Campaign

DUBAI, United Arab Emirates, July 23, 2025 (GLOBE NEWSWIRE) — Jetoptera and EANAN have marked another milestone in their collaborative development of the J-500, a 500-lb class VTOL-capable cargo drone, with the successful start of the turbocompressor mapping campaign; an essential step toward the realization of the aircraft's advanced propulsion capabilities. At the core of the J-500 is Jetoptera's proprietary Fluidic Propulsive System™ (FPS™), powered by a 250 kW turbocompressor developed by the USA based company, Jetoptera. This innovative propulsion architecture offers a modular and scalable solution designed for reduced noise, enhanced safety, and unmatched mission versatility. The First Engine to Test (FETT) was immediately followed by the Second Engine test campaign hosted by EANAN at its facilities in the UAE. The turbocompressor mapping is a critical step to validate the operability of this innovative modular propulsion system. The two-stage axial compressor driven by a free turbine is being tested for safe operability throughout the mission, from take-off to cruise to loitering, to vertical landing. 'The state-of-the-art setup that EANAN and Jetoptera have built is heavily instrumented to accurately characterize the efficiencies and operability of the heart of the FPS™,' said Dr. Andrei Evulet, Jetoptera CEO and former Technology Maturation and Integration Leader at GE Aerospace, where he led the successful test campaign of the GE9X High Pressure Compressor. 'In the first weeks of testing we obtained results that demonstrate operability of the compressor model design and support our plan to deliver the propulsion system for the J-500 as planned.' Two units are currently mapped; the results so far are promising. The Free Turbine Compressor (FTC-250) represents an unprecedented modularity in design, with the gas generator, FTC and FPS™ subsystems being able to operate in FPS™ configurations for V/STOL and low noise mission stages, as turbofan, bypassing the FPS™ for a dedicated nozzle for highest-speed mission stages. The gas generator itself can be used as a turbojet with the addition of a simple convergent nozzle. The Specific Fuel Consumption (SFC) decreases from the turbojet mode (which is the simplest and lightest application for conventional flight) to turbofan and finally to the FPS™, with targeted SFC 2-3 times lower than the turbojet's mode. The campaign also furthers the design of the controls of the aircraft. Unlike common UAVs that rely on rotors and propellers, the J-500 leverages a pneumatic system to distribute compressed air through dynamically actuated valves to the FPS™ thrusters, enabling precise control of the aircraft's attitude and maneuvering. Ulrich Weckx, CEO of EANAN, emphasized the significance of this partnership: 'The J-500 is a symbol of what can be achieved when innovation meets execution. Our collaboration with Jetoptera allows us to jointly develop a revolutionary propulsion-integrated airframe that leverages Jetoptera's unique FPS™ technology, while benefiting from EANAN's testing infrastructure in the UAE. This test campaign is not only a technical success; it's a strategic step forward in our shared vision to redefine advanced air mobility'. For information about this press release please contact Todd Newton todd@ Jetoptera, Inc. Facebook: Linkedin: Photos accompanying this announcement are available at:

StorageVault Reports 2025 Second Quarter Results and Increases Dividend
StorageVault Reports 2025 Second Quarter Results and Increases Dividend

Hamilton Spectator

time2 hours ago

  • Hamilton Spectator

StorageVault Reports 2025 Second Quarter Results and Increases Dividend

TORONTO, July 23, 2025 (GLOBE NEWSWIRE) — STORAGEVAULT CANADA INC. ('StorageVault' or the 'Corporation') (SVI-TSX) reported the Corporation's 2025 second quarter results and increases dividend. Iqbal Khan, Chief Financial Officer, commented: 'We are pleased to report strong second quarter results, with same store revenue growth of 6.6% and NOI growth of 5.2%, leading to a 5.4% increase in AFFO per common share. Our sustained organic performance, despite broader sector headwinds, demonstrates the strength and resilience of our platform. For the second half of the year, we will continue to be disciplined purchasers of assets and will remain opportunistic under our NCIB should our shares remain undervalued – as supported by recent private market transactions. At the same time, we will maintain a strong emphasis on cost control, while maximizing revenues, NOI and free cash flow.' 2025 Second Quarter Results Revenue for the second quarter of 2025 increased to $83.5 million compared to $74.1 million in Q2 2024 and net operating income ('NOI'), a non-IFRS measure, grew to $55.2 million from $49.9 million for the comparative period. Our cash flow from operations increased year over year and when combined with our financing, acquisitions and expansions resulted in an increased cash balance to $21.5 million at the end of the quarter. The Q2 2025 net loss of $6.2 million (net loss of $8.7 million for Q2 2024) is impacted by the following non-cash and non-recurring items – $27.3 million of depreciation and amortization, $0.1 million in stock based compensation, $1.1 million of interest accretion on convertible debentures, and deferred tax recovery of $2.0 million. Revenue and NOI from Existing Self Storage stores increased by 6.6% and 5.2%, compared to the same period last year. Funds from operations ('FFO'), a non-IFRS measure, were $20.3 million for Q2 2025 compared to $19.7 million in Q2 2024, a 3.4% increase year over year. Adjusted funds from operations ('AFFO'), a non-IFRS measure, were $22.9 million for Q2 2025 compared to $22.3 million in Q2 2024, a 3.0% increase. On a per basic common share basis, FFO and AFFO increased by 5.8% and 5.4%. Our Q2 2025 FFO and AFFO results are muted by operational and interest expenses related to lease-up stores acquired in fiscal 2024 ($127.0 million of the $215.0 million of acquisitions) and a nominal contribution from the 210,000 square feet of expanded and renovated space completed in Q4 2024 and Q1 2025. As these acquisitions and expansions stabilize, the Corporation expects to add an incremental annual $8.3 million of NOI within the next 3 years resulting in an equivalent incremental growth of FFO and AFFO. For a reconciliation of the above NOI, FFO, and AFFO amounts to IFRS, please see 'Non-IFRS Financial Measures' and the reconciliation tables below, and the Corporation's Management's Discussion & Analysis for the three and six months ended June 30, 2025 filed on SEDAR+ at . 2025 Six Months Year to Date Results Revenue for the six months ended June 30, 2025 increased to $159.8 million from $145.5 million, for the comparative period, a 9.8% increase, and NOI, a non-IFRS measure, grew to $102.9 million from $94.2 million, for the comparative period, a 9.2% increase. For the six months ended June 30, 2025, cash flow from operations was $47.0 million and when combined with our financing and investing activities resulted in a cash balance of $21.5 million. The net loss of $17.5 million for the six months ended June 30, 2025 (net loss of $16.6 million for 2024) is impacted by the following non-cash and non-recurring items – $53.9 million in depreciation and amortization, $1.0 million of unrealized loss on derivative financial instruments and deferred tax recovery of $4.1 million. Our Revenue and NOI from Existing Self Storage, a non-IFRS measure, increased by 4.0% and 4.0%, compared to the same period last year. FFO, a non-IFRS measure, were $35.7 million compared to $34.8 million for the same period in 2024, a 2.6% increase year over year. AFFO, a non-IFRS measure, were $39.9 million compared to $38.9 million for the same period in 2024, a 2.6% increase year over year. On a basic common per share basis, FFO and AFFO increased by 4.9% and 4.9%. For a reconciliation of the above NOI, FFO, and AFFO amounts to IFRS, please see 'Non-IFRS Financial Measures' and the reconciliation tables below, and ‎the Corporation's Management's Discussion & Analysis for the three and six months ended June 30, 2025 filed on SEDAR+ at . Increased Dividend StorageVault is increasing its Q3 2025 dividend by 0.5% to $0.002976 per common share. Our Strategy StorageVault is focused on owning and operating storage in the top markets in Canada. Our goal is to have multiple stores in each market, with complementary portable storage units and records management storage services, to take advantage of economies of scale. Our growth strategy is focused on acquisitions, organic growth, expansion of our existing stores and expansion of our portable storage and records management businesses. Further Information For comprehensive disclosure of StorageVault's performance for the three and six months ended June 30, 2025 and its financial position as at such date, please see StorageVault's Unaudited Interim Consolidated Financial Statements and Management's Discussion and Analysis for the three and six months ended June 30, 2025 filed on SEDAR+ at . Non-IFRS Financial Measures Management uses both IFRS and non-IFRS Measures to assess the financial and operating performance of the Corporation's operations. These non-IFRS Measures are not recognized measures under IFRS, do not have a standardized meaning under IFRS and are unlikely to be comparable to similar measures presented by other companies. The non-IFRS Measures referenced in this news release include the following: NOI, FFO, AFFO and Existing Self Storage, should not be viewed as an alternative to, in isolation from, or superior to, net income or cash flow from operations, or results from StorageVault's comprehensive operations, respectively, or other measures calculated in accordance with IFRS. NOI, FFO and AFFO should not be interpreted as an indicator of cash generated from operating activities and is not indicative of cash available to fund operating expenditures, or for the payment of cash distributions. Existing Self Storage should not be considered a measure of StorageVault's comprehensive operations. NOI, FFO, AFFO and Existing Self Storage are simply additional measures of operating performance which highlight trends in StorageVault's core business that may not otherwise be apparent when relying solely on IFRS financial measures. StorageVault's management also uses these non-IFRS measures in order to facilitate operating performance comparisons from period to period and to prepare operating budgets. In addition, the Corporation's definitions of NOI, FFO, AFFO and Existing Self Storage may differ from that of other issuers. Non-IFRS Financial Measures Reconciliation The following table reconciles Net Income (Loss) and Net Operating Income: The following table reconciles Net Income (Loss), and Funds from Operations and Adjusted Funds from Operations: The following table reconciles Existing Self Storage Revenue, Operating Costs and Net Operating Income: About StorageVault Canada Inc. As of June 30, 2025, StorageVault owned and operated 259 storage locations across Canada. StorageVault owns 228 of these locations plus over 5,000 portable storage units representing over 12.9 million rentable square feet on 752 acres of land. StorageVault also provides last mile storage and logistics' solutions and professional records management services, ‎such as document and media storage, imaging and shredding services. For further information, contact Mr. Steven Scott or Mr. Iqbal Khan: Tel: 1-877-622-0205 ir@ Follow us: Instagram: @accessstorageca @depotiumminientrepot @sentinelstorageca @cubeitportablestorage Facebook : /AccessStorageCA /Depotium /SentinelStorageCanada /Cubeit /FlexSpaceLogistics Forward-Looking Information: This news release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information regarding: the Corporation's expectations to continue to be a disciplined purchasers of assets, to remain opportunistic under its NCIB should Corporation's shares remain undervalued and to continue to maintain a strong emphasis on cost control while maximizing revenues, NOI and free cash flow; the Corporation's expectations to add an incremental annual $8.3 million of NOI within the next 3 years resulting in an equivalent incremental growth of FFO and AFFO; the Corporation's strategy, including, the Corporation being focused on owning and operating storage in the top markets in Canada, and the goal of having multiple stores in the top markets in Canada, with complementary portable storage units and records management storage services; and the Corporation's growth strategy, including a focus on acquisitions, organic growth, expansion of our existing stores and expansion of our portable storage and records management businesses. There can be no assurance that such forward-looking information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects StorageVault's current beliefs and is based on information currently available to StorageVault and on assumptions StorageVault believes are reasonable. These assumptions include, but are not limited to: the level of activity in the storage business and the economy generally; consumer interest in the Corporation's services and products; competition and StorageVault's competitive advantages; trends in the storage industry, including, increased growth and growth in the portable storage business; the availability of attractive and financially competitive asset acquisitions in the future; the closing of previously announced acquisitions; the revenue and costs from acquisitions and operations conducted in fiscal 2024 being extrapolated to the entire period for 2025 and being consistent with, and reproducible as, costs and revenue in future periods; and anticipated and unanticipated costs. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of StorageVault to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board of directors, third party or regulatory approvals; the actual results of StorageVault's future operations; competition; changes in legislation, including environmental legislation, affecting StorageVault; the timing and availability of external financing on acceptable terms; conclusions of economic evaluations and appraisals; lack of qualified, skilled labour or loss of key individuals; and the impact that the imposition of trade tariffs, particularly from the United States, may have on the global economy, and the economy in Canada in particular‎. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in StorageVault's disclosure documents on the SEDAR+ website at . Although StorageVault has attempted to identify important risks and factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of StorageVault as of the date of this news release and, accordingly, is subject to change after such date. However, StorageVault expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. The Corporation's expectations: to maximize revenue, NOI and free cash flow; and the Corporation's expectations to add an incremental annual $8.3 million of NOI within the next 3 years resulting in an equivalent incremental growth of FFO and AFFO, contained in this news release may be considered financial outlooks as defined by applicable securities legislation. Such information and any other financial outlooks have been approved by management of the Corporation as of the date hereof. Such financial outlooks are provided for the purpose of presenting information about management's current expectations and goals relating to the future business of the Corporation. Readers are cautioned that reliance on such information may not be appropriate for other purposes.

AirBoss to Release 2nd Quarter 2025 Earnings on August 7, 2025
AirBoss to Release 2nd Quarter 2025 Earnings on August 7, 2025

Hamilton Spectator

time2 hours ago

  • Hamilton Spectator

AirBoss to Release 2nd Quarter 2025 Earnings on August 7, 2025

NEWMARKET, Ontario, July 23, 2025 (GLOBE NEWSWIRE) — AirBoss of America Corp. (TSX: BOS) (OTCQX:ABSSF) (the 'Company' or 'AirBoss') today announced that it will release its second quarter 2025 results after markets close on August 7th, 2025. The release will be followed by a conference call to discuss the results on Friday, August 8, 2025, at 9:00 am ET. About AirBoss AirBoss of America is a diversified developer, manufacturer and provider of survivability solutions, advanced custom rubber compounds and finished rubber products that are designed to outperform in the most challenging environments. Founded in 1989, the company operates through two divisions. AirBoss Rubber Solutions is a North American custom rubber compounder with 500 million turn pounds of annual capacity. AirBoss Manufactured Products is a supplier of anti-vibration and rubber-molded solutions to the North American automotive market and other sectors, and also a global supplier of personal and respiratory protective equipment and technology for the defense, healthcare, medical and first responder communities, through its AirBoss Defense operations. The Company's shares trade on the TSX under the symbol BOS and on the OTCQX under the symbol ABSSF. Visit for more information.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store